Demystifying Stryker: Insights From 7 Analyst Reviews
In the latest quarter, 7 analysts provided ratings for Stryker (NYSE:SYK), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 2 | 2 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 2 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 1 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $426.14, along with a high estimate of $465.00 and a low estimate of $392.00. This current average reflects an increase of 0.31% from the previous average price target of $424.83.
Understanding Analyst Ratings: A Comprehensive Breakdown
A comprehensive examination of how financial experts perceive Stryker is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Danielle Antalffy | UBS | Raises | Neutral | $400.00 | $386.00 |
| Mike Matson | Needham | Raises | Buy | $454.00 | $448.00 |
| Ryan Zimmerman | BTIG | Raises | Buy | $412.00 | $410.00 |
| Lee Hambright | Bernstein | Raises | Outperform | $465.00 | $450.00 |
| David Turkaly | Citizens | Announces | Market Outperform | $440.00 | - |
| Richard Newitter | Truist Securities | Lowers | Hold | $392.00 | $400.00 |
| Joanne Wuensch | Citigroup | Lowers | Buy | $420.00 | $455.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Stryker. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Stryker compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Stryker's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Stryker's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Stryker analyst ratings.
Delving into Stryker's Background
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
Financial Milestones: Stryker's Journey
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Stryker's remarkable performance in 3M is evident. As of 31 December, 2025, the company achieved an impressive revenue growth rate of 18.39%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Stryker's net margin is impressive, surpassing industry averages. With a net margin of 11.84%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Stryker's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.84% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Stryker's ROA excels beyond industry benchmarks, reaching 1.79%. This signifies efficient management of assets and strong financial health.
Debt Management: Stryker's debt-to-equity ratio is below the industry average at 0.66, reflecting a lower dependency on debt financing and a more conservative financial approach.
What Are Analyst Ratings?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.